Tag: Multidisciplinary Association for Psychedelic Studies

FDA Grants Breakthrough Therapy Designation to MDMA (Ecstasy) for PTSD

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA (the main compound found in ecstasy) for the treatment of posttraumatic stress disorder (PTSD). The non-profit Multidisciplinary Association for Psychedelic Studies (MAPS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to MDMA for the …

Continue reading

DEA Approves Study of Cannabis in Treating PTSD

The Drug Enforcement Agency (DEA) has given approval to a study examining the benefits of cannabis in treating post traumatic stress disorder (PTSD). According to the Multidisciplinary Association for Psychedelic Studies (MAPS), who will be conducting the study, the DEA has given them approval to purchase whole-plant cannabis from the National Institute of Drug Abuse, …

Continue reading

DEA Approves Study of Ecstasy for Anxiety Associated with Life-Threatening Illness

The Drug Enforcement Adminsitration (DEA) has approved a study of MDMA (pure ecstasy) for the treatment of anxiety associated with terminal illnesses. “On March 13, 2015, the U.S. Drug Enforcement Administration approved the Schedule I license for Phil Wolfson, M.D., the Principal Investigator for our upcoming study of MDMA-assisted psychotherapy for anxiety associated with life-threatening …

Continue reading